Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenibPhilippe Saïag, Caroline Dutriaux, Charlée Nardin et al.|European Journal of Cancer|2021Cited by 13
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastasesCaroline Dutriaux, Philippe Saïag, Charlée Nardin et al.|European Journal of Cancer|2022Cited by 13
An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanomaPhilippe Saïag, Caroline Dutriaux, L. Machet et al.|Annals of Oncology|2018Cited by 1
An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasisCaroline Dutriaux, Philippe Saïag, C. Bédane et al.|Annals of Oncology|2019Cited by 1